Literature DB >> 3067976

Human cryptosporidiosis.

F G Crawford1, S H Vermund.   

Abstract

Cryptosporidium is an enteric coccidial protozoan recognized in humans in 1976. Since its manifestation as an acquired immunodeficiency syndrome (AIDS)-related infection, new diagnostic techniques have improved recognition of Cryptosporidium oocysts, making apparent its true prevalence in human populations. Cryptosporidium represents 5 to 15% of all enteric pathogens in children in warm climate countries. It is responsible for both endemic and epidemic disease. Day-care center spread is well known, and evidence is strong for person-to-person transmission. The spectrum of illness caused by Cryptosporidium is broad, and while self-limited in immunocompetent individuals, gastrointestinal symptoms can be severe. Asymptomatic infection has been described in population surveys and outbreak investigations. Severe dehydration with malabsorption and failure-to-thrive in children from developing countries has been attributed to this organism. Intractable, incurable diarrhea can be fetal in immunosuppressed adults. Cryptosporidiosis in human immunodeficiency virus-infected individuals is declining in frequency in New York City, possibly reflecting changing sexual behaviors and comparatively low infectivity. No effective treatment for Cryptosporidium has been documented, but clinical trials are in progress.

Entities:  

Mesh:

Year:  1988        PMID: 3067976     DOI: 10.3109/10408418809104469

Source DB:  PubMed          Journal:  Crit Rev Microbiol        ISSN: 1040-841X            Impact factor:   7.624


  31 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 2.  In vitro cultivation of cryptosporidium species.

Authors:  Michael J Arrowood
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

3.  In vitro activities of lytic peptides against the sporozoites of Cryptosporidium parvum.

Authors:  M J Arrowood; J M Jaynes; M C Healey
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

4.  Monoclonal antibody immunotherapy in nude mice persistently infected with Cryptosporidium parvum.

Authors:  J M Bjorneby; B D Hunsaker; M W Riggs; L E Perryman
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

5.  New mouse models for chronic Cryptosporidium infection in immunodeficient hosts.

Authors:  B L Ungar; J A Burris; C A Quinn; F D Finkelman
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

6.  Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model.

Authors:  Nigel Yarlett; W Ray Waters; James A Harp; Michael J Wannemuehler; Mary Morada; Josephine Bellcastro; Steve J Upton; Laurence J Marton; Benjamin J Frydman
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

7.  Prevalence of Cryptosporidium in children with enteritis in southern Italy.

Authors:  O Brandonisio; A Marangi; M A Panaro; R Marzio; M I Natalicchio; P Zizzadoro; U De Santis
Journal:  Eur J Epidemiol       Date:  1996-04       Impact factor: 8.082

8.  Inactivation of Cryptosporidium parvum oocysts in fresh apple cider by UV irradiation.

Authors:  D E Hanes; R W Worobo; P A Orlandi; D H Burr; M D Miliotis; M G Robl; J W Bier; M J Arrowood; J J Churey; G J Jackson
Journal:  Appl Environ Microbiol       Date:  2002-08       Impact factor: 4.792

Review 9.  Cryptosporidiosis.

Authors:  W L Current; L S Garcia
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

10.  Effects of ozone, chlorine dioxide, chlorine, and monochloramine on Cryptosporidium parvum oocyst viability.

Authors:  D G Korich; J R Mead; M S Madore; N A Sinclair; C R Sterling
Journal:  Appl Environ Microbiol       Date:  1990-05       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.